The first approved drug to slow the progression of the illness will come with a strong safety warning about potentially life-threatening side effects.
You must log in or register to comment.
I was all excited until the blurb about life threatening side effects:(
Obviously this is still a good step forward, but if it works, I wonder if they can use that knowledge to lessen the risk of death…
Leqembi, from Japanese drugmaker Eisai and U.S.-based drugmaker Biogen, targets a type of protein in the brain called beta-amyloid, long thought by scientists to be one of the underlying causes of Alzheimer’s disease.
Biologics are the medication therapy of the future. We just need to be able to get them accessible for patients.
